Protocol Ledger

NCT06524375 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allo

Interventional Phase II clinical trial protocol NCT06524375 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-09 Enrollment: 118 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06524375
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)118 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06524375
Protocol FieldVerified Registry Value
NCT IdentifierNCT06524375
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment118 participants (ACTUAL)
Registered Start Date2024-08-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06524375
Hospital Research SiteLocationSite Profile
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI